Document Detail

Predicting cancer drug mechanisms of action using molecular network signatures.
MedLine Citation:
PMID:  23287973     Owner:  NLM     Status:  MEDLINE    
Molecular signatures are a powerful approach to characterize novel small molecules and derivatized small molecule libraries. While new experimental techniques are being developed in diverse model systems, informatics approaches lag behind these exciting advances. We propose an analysis pipeline for signature based drug annotation. We develop an integrated strategy, utilizing supervised and unsupervised learning methodologies that are bridged by network based statistics. Using this approach we can: 1, predict new examples of drug mechanisms that we trained our model upon; 2, identify "New" mechanisms of action that do not belong to drug categories that our model was trained upon; and 3, update our training sets with these "New" mechanisms and accurately predict entirely distinct examples from these new categories. Thus, not only does our strategy provide statistical generalization but it also offers biological generalization. Additionally, we show that our approach is applicable to diverse types of data, and that distinct biological mechanisms characterize its resolution of categories across different data types. As particular examples, we find that our predictive resolution of drug mechanisms from mRNA expression studies relies upon the analog measurement of a cell stress-related transcriptional rheostat along with a transcriptional representation of cell cycle state; whereas, in contrast, drug mechanism resolution from functional RNAi studies rely upon more dichotomous (e.g., either enhances or inhibits) association with cell death states. We believe that our approach can facilitate molecular signature-based drug mechanism understanding from different technology platforms and across diverse biological phenomena.
Justin R Pritchard; Peter M Bruno; Michael T Hemann; Douglas A Lauffenburger
Related Documents :
23287973 - Predicting cancer drug mechanisms of action using molecular network signatures.
10615573 - Globalization, pharmaceutical pricing, and south african health policy: managing confro...
23822613 - Methylenedioxypyrovalerone ("bath salts"),related death: case report and review of the ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2013-01-04
Journal Detail:
Title:  Molecular bioSystems     Volume:  9     ISSN:  1742-2051     ISO Abbreviation:  Mol Biosyst     Publication Date:  2013 Jul 
Date Detail:
Created Date:  2013-06-05     Completed Date:  2013-12-30     Revised Date:  2014-04-25    
Medline Journal Info:
Nlm Unique ID:  101251620     Medline TA:  Mol Biosyst     Country:  England    
Other Details:
Languages:  eng     Pagination:  1604-19     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents* / pharmacology
Cluster Analysis
Gene Expression Profiling*
Gene Expression Regulation, Neoplastic* / drug effects
Models, Biological*
RNA Interference
Support Vector Machines
Tumor Markers, Biological / genetics*
Grant Support
P30 CA014051/CA/NCI NIH HHS; T32 GM007287/GM/NIGMS NIH HHS; U54 CA112967/CA/NCI NIH HHS; U54-CA112967/CA/NCI NIH HHS
Reg. No./Substance:
0/Antineoplastic Agents; 0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-...
Next Document:  The Influence of Radiation Therapy on Dental Implantology.